Krystal Biotech Quarterly Income Statement
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech revenue and earnings
In the quarter ended Jun 30, 2026, Krystal Biotech generated $119.2 million in revenue, up 24.1% from the same quarter a year earlier. Net income was $54.8 million (+42.9% year over year), for a net margin of 45.9% versus a median of 48.0% in the prior 5 quarters. Operating margin was 49.0%.
Diluted earnings per share came in at $1.79, up from $1.29.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 119.22M | 116.36M | 107.11M | 97.80M | 96.04M | 88.18M | 91.14M | 83.84M | 70.28M | 45.25M | 42.14M | 8.56M |
| Revenue growth (YoY) | +24.14% | +31.95% | +17.52% | +16.65% | +36.65% | +94.88% | +116.26% | +879.91% | — | — | — | — |
| Operating Expenses | 60.80M | 62.67M | 62.84M | 56.43M | 56.64M | 51.93M | 49.76M | 61.37M | 61.72M | 51.93M | 38.90M | 34.55M |
| Research & Development | 14.52M | 15.33M | 14.79M | 14.59M | 14.41M | 14.26M | 13.53M | 13.51M | 15.58M | 10.96M | 11.37M | 10.63M |
| Selling, General & Admin | 39.85M | 41.01M | 41.45M | 37.58M | 35.07M | 32.65M | 31.29M | 28.67M | 27.63M | 26.06M | 24.65M | 23.70M |
| Operating Income | 58.42M | 53.69M | 44.27M | 41.37M | 39.40M | 36.25M | 41.38M | 22.47M | 8.57M | -6.68M | 3.25M | -25.99M |
| Pretax Income | 66.08M | 61.44M | 51.13M | 47.97M | 46.77M | 43.60M | 48.61M | 29.77M | 16.05M | 932.00K | 10.66M | 80.75M |
| Income Tax | 11.31M | 5.51M | -269.00K | -31.40M | 8.44M | 7.86M | 3.13M | 2.59M | 477.00K | 0 | 1.97M | 0 |
| Net Income | 54.77M | 55.93M | 51.40M | 79.36M | 38.33M | 35.73M | 45.48M | 27.18M | 15.57M | 932.00K | 8.69M | 80.75M |
| Net Income growth (YoY) | +42.87% | +56.53% | +13.02% | +192.00% | +146.23% | +3734.01% | +423.23% | -66.34% | — | — | — | — |
| EPS (Basic) | 1.85 | 1.91 | 1.77 | 2.74 | 1.33 | 1.24 | 1.60 | 0.95 | 0.54 | 0.03 | 0.53 | 2.88 |
| EPS (Diluted) | 1.79 | 1.83 | 1.69 | 2.66 | 1.29 | 1.20 | 1.53 | 0.91 | 0.53 | 0.03 | 0.61 | 2.79 |
| Shares Outstanding (Basic) | 29.53M | 29.29M | — | 28.95M | 28.91M | 28.82M | — | 28.72M | 28.60M | 28.30M | — | 28.04M |
| Shares Outstanding (Diluted) | 30.66M | 30.51M | — | 29.83M | 29.75M | 29.87M | — | 29.90M | 29.64M | 29.29M | — | 28.89M |
| EBITDA | 59.82M | 55.21M | 45.83M | 42.77M | 40.70M | 37.66M | 42.74M | 23.77M | 10.37M | -5.26M | 4.77M | -25.17M |
| Operating Margin | 49.00% | 46.14% | 41.33% | 42.30% | 41.02% | 41.11% | 45.40% | 26.80% | 12.19% | -14.77% | 7.71% | -303.80% |
| Net Margin | 45.94% | 48.07% | 47.99% | 81.15% | 39.91% | 40.52% | 49.90% | 32.42% | 22.15% | 2.06% | 20.63% | 943.75% |
This table shows 12 quarterly periods of Krystal Biotech's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow KRYS's reporting calendar. What is a income statement?